Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial | Zendy

Daniel F. Hoft | Zendy; Azra Blazevic | Zendy; Asmir Selimovic | Zendy; Aldin Turan | Zendy; Jan Tennant | Zendy; Getahun Abate | Zendy; John P. Fulkerson | Zendy; Daniel E. Zak | Zendy; Robert Walker | Zendy; Bruce McClain | Zendy; Jerry Sadoff | Zendy; Judy Scott | Zendy; Barbara Shepherd | Zendy; Jasur Ishmukhamedov | Zendy; David A. Hokey | Zendy; Veerabadran Dheenadhayalan | Zendy; Steven G. Smith | Zendy; Lynn M. Amon | Zendy; Garnet Navarro | Zendy; Rebecca Podyminogin | Zendy; Alan Aderem | Zendy; Lew Barker | Zendy; Michael J. Brennan | Zendy; Robert S. Wallis | Zendy; Anne A. Gershon | Zendy; Michael D. Gershon | Zendy; Sharon Steinberg | Zendy

Open Access

Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial

Author(s) -

Daniel F. Hoft,

Azra Blazevic,

Asmir Selimovic,

Aldin Turan,

Jan Tennant,

Getahun Abate,

John P. Fulkerson,

Daniel E. Zak,

Robert Walker,

Bruce McClain,

Jerry Sadoff,

Judy Scott,

Barbara Shepherd,

Jasur Ishmukhamedov,

David A. Hokey,

Veerabadran Dheenadhayalan,

Steven G. Smith,

Lynn M. Amon,

Garnet Navarro,

Rebecca Podyminogin,

Alan Aderem,

Lew Barker,

Michael J. Brennan,

Robert S. Wallis,

Anne A. Gershon,

Michael D. Gershon,

Sharon Steinberg

Publication year - 2016

Publication title -

ebiomedicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.596

H-Index - 63

ISSN - 2352-3964

DOI - 10.1016/j.ebiom.2016.04.010

Subject(s) - immunogenicity , medicine , recombinant dna , virology , bcg vaccine , randomized controlled trial , immunology , vaccination , biology , antibody , gene , genetics

We report a first-in-human trial evaluating safety and immunogenicity of a recombinant BCG, AERAS-422, over-expressing TB antigens Ag85A, Ag85B, and Rv3407 and expressing mutant perfringolysin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research